surmount-1 tirzepatide non-diabetic obesity weight loss as Compared with Semaglutide for the Treatment of SURMOUNT-1
Description
This binds highly to albumin in the plasma, and prolongs half-life
When stopping Tirzepatide abruptly, some patients may experience mild to moderate weight gain
Concentration ties mass to volume
This guide breaks down the testing data, the availability timeline, the quality concerns, and the alternatives
All prescriptions are written at the sole discretion of the licensed provider
Dose escalation phase (titration) After the first 4 weeks, if the medication is well tolerated, your healthcare provider will typically increase the dosage to 5 mg once weekly for the next 4 weeks (weeks 5-8)
